Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT

Among 4365 WSG-ADAPT-HR+/HER2- patients, N0-1 cases receiving ET after ET-response and meeting NATALEE but not monarchE criteria had only slightly inferior outcomes vs. the low-risk group. Assuming a hazard ratio of 0.7 for a ribociclib effect in NATALEE, an absolute benefit of approximately 2% fewer dDFS events after 5 years could be expected in this group based on the WSG-ADAPT-HR+/HER2- experience. ET-response evaluation can refine prognosis to better inform shared decision-making in this intermediate-risk group.

Authors

Institutions

Publication Details

Journal
Breast Care
Published
2026-02-12
DOI
https://doi.org/10.1159/000550825
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT

Matthias Christgen, Ronald Kates, Christine zu Eulenburg, Sandy Burmeister et al.
Breast Care
Advanced Breast Cancer Therapies
article

Refining Risk Assessment for Adjuvant CDK4/6 Inhibitors beyond Trial Inclusion Criteria: Integrating Recurrence Score and Endocrine Responsiveness according to ADAPT

Matthias Christgen, Ronald Kates, Christine zu Eulenburg, Sandy Burmeister, Rick Baehner, Oleg Gluz, Ulrike Nitz, Michael Braun, Nadia Harbeck, Claudia Schumacher, Silke Polata, Eva-Maria Grischke, Bahriye Aktas, Kerstin Luedtke-Heckenkamp, Sherko Kuemmel, Hans Heinrich Kreipe, Maren Darsow, Helmut Forstbauer, Monika Graeser
article en

Abstract

Among 4365 WSG-ADAPT-HR+/HER2- patients, N0-1 cases receiving ET after ET-response and meeting NATALEE but not monarchE criteria had only slightly inferior outcomes vs. the low-risk group. Assuming a hazard ratio of 0.7 for a ribociclib effect in NATALEE, an absolute benefit of approximately 2% fewer dDFS events after 5 years could be expected in this group based on the WSG-ADAPT-HR+/HER2- experience. ET-response evaluation can refine prognosis to better inform shared decision-making in this intermediate-risk group.

Breast Care
Witten/Herdecke University (DE), Universität Hamburg (DE), Medizinische Hochschule Hannover (DE), Nielsen (Germany) (DE), St. Elisabeth-Hospital Bochum (DE), University Medical Center Hamburg-Eppendorf (DE), Luisenkrankenhaus (DE), Essen University Hospital (DE), Breast Center (CH), University Children's Hospital Tübingen (DE), University Hospital Leipzig (DE), Waldkrankenhaus Protestant Hospital (DE), Praxis für Hämatologie und Onkologie (DE), Evangelisches Krankenhaus Bethesda Mönchengladbach (DE), Medizinische Hochschule Brandenburg Theodor Fontane (DE), Kliniken Essen-Mitte (DE), Charité - Universitätsmedizin Berlin (DE), University of Tübingen (DE), Ludwig-Maximilians-Universität München (DE)
Amgen, Celgene
Good health and well-being
Openalex Percentile: Top 60%
Advanced Breast Cancer Therapies
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.